[Active stents: towards total prevention of restenosis?].
To avoid in-stent restenosis, a new technologic approach with "coated" stents may deliver local cytostatic products (sirolimus, paclitaxel, tacrolimus...). At this time, present clinical studies validate the importance of these active coated stents in sub-groups of patients with diabetes, long lesions, small vessels and proximal left anterior descending coronary lesions.
Chevalier
B
B
Centre cardiologique du Nord, 32-36, avenue des Moulins-Gémeaux, 93207 Saint-Denis, France.
D023903:Coronary Restenosis / Q000517:prevention & control*; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage*; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D016559:Tacrolimus / Q000008:administration & dosage*
D017239:Paclitaxel; D020123:Sirolimus; D016559:Tacrolimus